Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | cytidine and deoxycytidylate deaminase zinc-binding region domain-containing protein | 0.0218 | 1 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0064 | 0 | 0.5 |
Giardia lamblia | Cytidine deaminase | 0.0218 | 1 | 0.5 |
Trypanosoma brucei | cytidine deaminase | 0.0218 | 1 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0064 | 0 | 0.5 |
Onchocerca volvulus | 0.0218 | 1 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0 | 0.5 |
Leishmania major | cytidine deaminase-like protein | 0.0218 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable cytidine deaminase Cdd (cytidine aminohydrolase) (cytidine nucleoside deaminase) | 0.0218 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0 | 0.5 |
Echinococcus multilocularis | cytidine deaminase | 0.0218 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0 | 0.5 |
Trypanosoma cruzi | cytidine deaminase-like protein | 0.0218 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0064 | 0 | 0.5 |
Onchocerca volvulus | 0.0218 | 1 | 0.5 | |
Entamoeba histolytica | cytidine deaminase, putative | 0.0218 | 1 | 0.5 |
Mycobacterium ulcerans | cytidine deaminase | 0.0218 | 1 | 0.5 |
Mycobacterium leprae | PROBABLE CYTIDINE DEAMINASE CDD (CYTIDINE AMINOHYDROLASE) (CYTIDINE NUCLEOSIDE DEAMINASE) | 0.0218 | 1 | 0.5 |
Trichomonas vaginalis | cytidine deaminase, putative | 0.0218 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0 | 0.5 |
Trichomonas vaginalis | cytidine deaminase, putative | 0.0218 | 1 | 0.5 |
Trypanosoma cruzi | cytidine deaminase-like protein, putative | 0.0218 | 1 | 0.5 |
Echinococcus granulosus | cytidine deaminase | 0.0218 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 37 uM | Cytotoxicity in the absence of hypoxanthine and presence of thymidine against CCRF-CEM cell line | ChEMBL. | 10888335 |
IC50 (functional) | = 37 uM | Cytotoxicity in the absence of hypoxanthine and presence of thymidine against CCRF-CEM cell line | ChEMBL. | 10888335 |
IC50 (functional) | = 49 uM | Cytotoxicity in the absence of thymidine and hypoxanthine against CCRF-CEM cell line | ChEMBL. | 10888335 |
IC50 (functional) | = 49 uM | Cytotoxicity in the absence of thymidine and hypoxanthine against CCRF-CEM cell line | ChEMBL. | 10888335 |
IC50 (functional) | = 50 uM | Cytotoxicity in the absence of thymidine and presence of hypoxanthine against CCRF-CEM cell line | ChEMBL. | 10888335 |
IC50 (functional) | = 50 uM | Cytotoxicity in the absence of thymidine and presence of hypoxanthine against CCRF-CEM cell line | ChEMBL. | 10888335 |
IC50 (functional) | = 54 uM | Cytotoxicity in the presence of thymidine and hypoxanthine against CCRF-CEM cell line | ChEMBL. | 10888335 |
IC50 (functional) | = 54 uM | Cytotoxicity in the presence of thymidine and hypoxanthine against CCRF-CEM cell line | ChEMBL. | 10888335 |
Inhibition (binding) | 0 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase) after 3 min at 250 uM; Not active | ChEMBL. | 10888335 |
Inhibition (binding) | = 6 % | In vitro inhibitory activity against Aminoimidazole carboxamide ribonucleotide transformylase pre-incubed for 12 hr at 250 microM | ChEMBL. | 10888335 |
Inhibition (binding) | = 6 % | In vitro inhibitory activity against Aminoimidazole carboxamide ribonucleotide transformylase pre-incubed for 12 hr at 250 microM | ChEMBL. | 10888335 |
Inhibition (binding) | = 32 % | In vitro inhibitory activity at 250 microM concentration against Glycinamide ribonucleotide transformylase (GAR Tfase) pre-incubation time (6 hr). | ChEMBL. | 10888335 |
Inhibition (binding) | = 32 % | In vitro inhibitory activity at 250 microM concentration against Glycinamide ribonucleotide transformylase (GAR Tfase) pre-incubation time (6 hr). | ChEMBL. | 10888335 |
Inhibition (binding) | = 66 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase+GAR) pre-incubation of 6 h at 250 microM concentration | ChEMBL. | 10888335 |
Inhibition (binding) | = 66 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase+GAR) pre-incubation of 6 h at 250 microM concentration | ChEMBL. | 10888335 |
Inhibition (binding) | = 67 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase) following 30 min pre-incubation at 250 microM concentration | ChEMBL. | 10888335 |
Inhibition (binding) | = 67 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase) following 30 min pre-incubation at 250 microM concentration | ChEMBL. | 10888335 |
Inhibition (binding) | = 90 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase+GAR) following 30 min pre-incubation at 250 microM concentration | ChEMBL. | 10888335 |
Inhibition (binding) | = 90 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase+GAR) following 30 min pre-incubation at 250 microM concentration | ChEMBL. | 10888335 |
Inhibition (binding) | = 91 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase) following 3 min pre-incubation at 250 microM concentration | ChEMBL. | 10888335 |
Inhibition (binding) | = 91 % | In vitro inhibitory activity against Glycinamide ribonucleotide transformylase (GAR Tfase) following 3 min pre-incubation at 250 microM concentration | ChEMBL. | 10888335 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.